Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims & Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three months.

The telehealth company’s stock has surged to almost double year to date. However, over the last three months, the stock has fallen around 10%. In June, the stock cratered almost 30% when Novo Nordisk discontinued working with the company in relation to direct access to Wegovy (semaglutide).

Novo Nordisk alleged that Hims & Hers Health failed to adhere to the law prohibiting mass sales of compounded drugs under the false guise of “personalization” and is disseminating deceptive marketing that risks patient safety.

Also Read: Eli Lilly’s Rare Weight Loss Data Miss Could Benefit Competitors

Hims & Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Regulators typically ...